journal
MENU ▼
Read by QxMD icon Read
search

Annals of Oncology: Official Journal of the European Society for Medical Oncology

journal
https://read.qxmd.com/read/30785198/capecitabine-plus-oxaliplatin-versus-gemcitabine-plus-oxaliplatin-as-first-line-therapy-for-advanced-biliary-tract-cancers-a-multicenter-open-label-randomized-phase-three-non-inferiority-trial
#1
Seung Tae Kim, Jung Hun Kang, Jeeyun Lee, Hyun Woo Lee, Sung Young Oh, Joung Soon Jang, Myung Ah Lee, Byeong Seok Sohn, So Young Yoon, Hye Jin Choi, Ji Hyong Hong, Min-Ji Kim, Seonwoo Kim, Young Suk Park, Joon Oh Park, Ho Yeong Lim
BACKGROUND: Capecitabine plus oxaliplatin (XELOX) has shown modest activity and tolerable toxicity in a phase two trial for biliary tract cancers (BTCs). Meanwhile, gemcitabine plus oxaliplatin (GEMOX) has been the reference arm in recent phase two and three trials for BTCs. We aimed to investigate the efficacy of XELOX versus GEMOX as first-line therapy for advanced BCTs. PATIENTS AND METHODS: In this open-label, randomized, phase three, non-inferiority trial, we randomly selected patients with metastatic BCTs to receive GEMOX (gemcitabine 1000 mg/m2 on days 1 and 8, and oxaliplatin 100 mg/m2 on day 1) or XELOX (capecitabine 1000 mg/m2, twice daily, on days 1-14 and oxaliplatin 130 mg/m2 on day 1) as first-line treatment, given every 3 weeks, totaling 8 cycles...
February 20, 2019: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://read.qxmd.com/read/30778525/value-assessment-frameworks-in-oncology-championing-concordance-through-shared-standards
#2
M Bertagnolli, J Tabernero
No abstract text is available yet for this article.
February 18, 2019: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://read.qxmd.com/read/30778520/de-escalated-therapy-for-hr-her2-breast-cancer-patients-with-ki67-response-after-2-weeks-letrozole-results-of-the-perelisa-neoadjuvant-study
#3
V Guarneri, M V Dieci, G Bisagni, A Frassoldati, G V Bianchi, G L De Salvo, E Orvieto, L Urso, T Pascual, L Paré, P Galván, M Ambroggi, C A Giorgi, G Moretti, G Griguolo, R Vicini, A Prat, P F Conte
BACKGROUND: In HER2+ breast cancers, neoadjuvant trials of chemotherapy plus anti-HER2 treatment consistently showed lower pathologic complete response (pCR) rates in hormone receptor (HR) positive vs negative tumors. The PerELISA study was aimed to evaluate the efficacy of a de-escalated, chemotherapy-free neoadjuvant regimen in HR+/HER2+ breast cancer patients selected on the basis of Ki67 inhibition after 2-weeks letrozole. PATIENTS AND METHODS: PerELISA is a phase II, multicentric study for postmenopausal patients with HR+/HER2+ operable breast cancer...
February 18, 2019: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://read.qxmd.com/read/30768148/treatment-in-metastatic-melanoma-time-to-re-think
#4
Dirk Schadendorf, Elisabeth Livingstone, Lisa Zimmer
No abstract text is available yet for this article.
February 15, 2019: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://read.qxmd.com/read/30753264/machine-learning-based-predictors-for-immune-checkpoint-inhibitor-therapy-of-non-small-cell-lung-cancer
#5
M Wiesweg, F Mairinger, H Reis, M Goetz, R F H Walter, T Hager, M Metzenmacher, W E E Eberhardt, A McCutcheon, J Köster, M Stuschke, C Aigner, K Darwiche, K W Schmid, S Rahmann, M Schuler
No abstract text is available yet for this article.
February 11, 2019: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://read.qxmd.com/read/30753274/the-immune-profile-of-small-her2-positive-breast-cancers-a-secondary-analysis-from-the-apt-trial
#6
R Barroso-Sousa, W T Barry, H Guo, D Dillon, Y B Tan, K Fuhrman, W Osmani, A Getz, M Baltay, C Dang, D Yardley, B Moy, P K Marcom, E A Mittendorf, I E Krop, E P Winer, S M Tolaney
Background: Previous data suggest that the immune microenvironment plays a critical role in HER2-positive breast cancer, however there is little known about the immune profiles of small HER2-positive tumors. In this study we aimed to characterize the immune microenvironment of small HER2-positive breast cancers included in the APT trial, and to correlate the immune markers with pathological and molecular tumor characteristics. Patients and Methods: The APT trial was a multicenter, single-arm phase II study of paclitaxel and trastuzumab in patients with node-negative HER2-positive breast cancer...
February 7, 2019: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://read.qxmd.com/read/30753272/overall-survival-and-updated-progression-free-survival-outcomes-in-a-randomized-phase-2-study-of-combination-cediranib-and-olaparib-versus-olaparib-in-relapsed-platinum-sensitive-ovarian-cancer
#7
J F Liu, W T Barry, M Birrer, J-M Lee, R J Buckanovich, G F Fleming, B J Rimel, M K Buss, S R Nattam, J Hurteau, W Luo, J Curtis, C Whalen, E C Kohn, S P Ivy, U A Matulonis
Background: Olaparib is a poly(ADP-ribose) polymerase (PARP) inhibitor and cediranib is an oral anti-angiogenic. In the primary analysis of this phase 2 study, combination cediranib/olaparib improved progression-free survival (PFS) compared to olaparib alone in relapsed platinum-sensitive ovarian cancer. This updated analysis was conducted to characterize overall survival (OS) and update PFS outcomes. Patients and Methods: 90 patients were enrolled to this randomized, open-label, phase 2 study between October 2011 and June 2013 across nine United States-based academic centers...
February 7, 2019: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://read.qxmd.com/read/30753271/recent-advances-in-circulating-nucleic-acids-in-oncology
#8
A Otandault, P Anker, Z Al Amir Dache, V Guillaumon, R Meddeb, B Pastor, E Pisareva, C Sanchez, R Tanos, G Tousch, H Schwarzenbach, A R Thierry
Circulating cell-free DNA (cfDNA) is one of the fastest growing and most exciting areas in oncology in recent years. Its potential clinical uses cover now each phase of cancer patient management care (predictive information, detection of the minimal residual disease, early detection of resistance, treatment monitoring, recurrence surveillance, and cancer early detection/screening). This review relates the recent advances in the application of circulating DNA or RNA in oncology building on unpublished or initial findings/work presented at the 10th international symposium on circulating nucleic acids in plasma and serum (CNAPS) held in Montpellier from the 20th to the 22nd of September 2017...
February 7, 2019: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://read.qxmd.com/read/30753270/body-size-and-obesity-during-adulthood-and-risk-of-lympho-hematopoietic-cancers-an-update-of-the-wcrf-aicr-systematic-review-of-published-prospective-studies
#9
L Abar, J G Sobiecki, M Cariolou, N Nanu, A R Vieira, C Stevens, D Aune, D C Greenwood, D S M Chan, T Norat
Background: To summarise the evidence on the associations between body mass index (BMI) and BMI in early adulthood, height, waist circumference (WC) and waist to hip ratio (WHR), and risk of lympho-hematopoietic cancers. Method: We conducted a meta-analysis of prospective studies and identified relevant studies published up to December 2017 by searching PubMed. A random effects model was used to calculate dose-response summary relative risks (RRs). Results: Our findings showed BMI, and BMI in early adulthood (aged 18-21 years) is associated with the risk of Hodgkin's and Non-Hodgkin's lymphoma (HL and NHL), Diffuse Large Beta Cell Lymphoma (DLBCL), Leukaemia including Acute and Chronic Myeloid Lymphoma (AML and CML), and Chronic Lymphocytic Leukaemia (CLL) and Multiple Myeloma...
February 7, 2019: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://read.qxmd.com/read/30753266/future-of-checkpoint-blockade-in-triple-negative-breast-cancer-combination-strategies-to-lead-the-way
#10
M L Telli, S Vinayak
No abstract text is available yet for this article.
February 7, 2019: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://read.qxmd.com/read/30753265/searching-for-the-needle-in-the-haystack-deconvoluting-the-evolutionary-dynamics-of-residual-disease-in-human-glioblastoma
#11
S T C Shepherd, K Litchfield, S Turajlic
No abstract text is available yet for this article.
February 7, 2019: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://read.qxmd.com/read/30726873/doxorubicin-plus-the-igf-1r-antibody-cixutumumab-in-soft-tissue-sarcoma-a-phase-i-study-using-the-tite-crm-model
#12
R Chugh, K A Griffith, E J Davis, D G Thomas, J D Zavala, G Metko, B Brockstein, S D Undevia, W M Stadler, S M Schuetze
No abstract text is available yet for this article.
February 5, 2019: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://read.qxmd.com/read/30721924/meeting-report-from-the-joint-iarc-nci-international-cancer-seminar-series-a-focus-on-colorectal-cancer
#13
M J Gunter, S Alhomoud, M Arnold, H Brenner, J Burn, G Casey, A T Chan, A J Cross, E Giovannucci, R Hoover, R Houlston, M Jenkins, P Laurent-Puig, U Peters, D Ransohoff, E Riboli, R Sinha, Z K Stadler, P Brennan, S J Chanock
Despite significant progress in our understanding of the etiology, biology and genetics of colorectal cancer, as well as important clinical advances, it remains the third most frequently diagnosed cancer worldwide and is the second leading cause of cancer death. Based on demographic projections, the global burden of colorectal cancer would be expected to rise by 72% from 1.8 million new cases in 2018 to over 3 million in 2040 with substantial increases anticipated in low and middle income countries. In this meeting report, we summarize the content of a joint workshop led by the National Cancer Institute (NCI) and the International Agency for Research on Cancer (IARC) which was held to summarize the important achievements that have been made in our understanding of colorectal cancer etiology, genetics, early detection and treatment and to identify key research questions that remain to be addressed...
February 5, 2019: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://read.qxmd.com/read/30715154/improving-our-knowledge-in-pd-l1-testing-in-lung-cancer-the-archival-sample-is-promoted
#14
A Morabito
No abstract text is available yet for this article.
February 2, 2019: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://read.qxmd.com/read/30715147/model-informed-drug-development-approach-supporting-approval-of-the-4-week-q4w-dosing-schedule-for-nivolumab-opdivo-across-multiple-indications-a-regulatory-perspective
#15
Y Bi, J Liu, B Furmanski, Z Hong, J Yu, C Osgood, A Ward, P Keegan, B P Booth, A Rahman, Y Wang
Background: A nivolumab dosage regimen of 480 mg intravenously (IV) every 4 weeks (Q4W) was approved by FDA for the majority of the approved indications for nivolumab. Methods: The proposed new dosage regimen was supported by pharmacokinetic modeling and simulation, dose/exposure response relationships for efficacy and safety in the indicated patient populations, and the clinical safety data with the 480 mg Q4W dosage regimen. Pharmacokinetic exposures achieved with 480 mg Q4W were predicted for 4,166 patients in 21 clinical studies with various types of solid and hematological tumors...
February 2, 2019: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://read.qxmd.com/read/30715217/editorial-annals-of-oncology
#16
S Ekman
No abstract text is available yet for this article.
February 1, 2019: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://read.qxmd.com/read/30715202/hepatocellular-carcinoma-esmo-clinical-practice-guidelines-for-diagnosis-treatment-and-follow-up
#17
A Vogel, A Cervantes, I Chau, B Daniele, J M Llovet, T Meyer, J-C Nault, U Neumann, J Ricke, B Sangro, P Schirmacher, C Verslype, C J Zech, D Arnold, E Martinelli
No abstract text is available yet for this article.
January 31, 2019: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://read.qxmd.com/read/30715161/genomic-alterations-in-breast-cancer-level-of-evidence-for-actionability-according-to-esmo-scale-for-clinical-actionability-of-molecular-targets-escat
#18
R Condorelli, F Mosele, B Verret, T Bachelot, P L Bedard, J Cortes, D M Hyman, D Juric, I Krop, I Bieche, C Saura, C Sotiriou, F Cardoso, S Loibl, F Andre, N C Turner
Better knowledge of the tumor genomic landscapes has helped to develop more effective targeted drugs. However, there is no tool to interpret targetability of genomic alterations assessed by next generation sequencing in the context of clinical practice. Our aim is to rank the level of evidence of individual recurrent genomic alterations observed in breast cancer based on the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) in order to help the clinicians to prioritize treatment. Analyses of databases suggested that there are around 40 recurrent driver alterations in breast cancer...
January 31, 2019: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://read.qxmd.com/read/30715160/making-adjuvant-therapy-decisions-with-uncertain-data
#19
B Gyawali, V Prasad
No abstract text is available yet for this article.
January 31, 2019: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://read.qxmd.com/read/30715159/of-mice-and-men-lost-in-translation
#20
R Groisberg, A Maitra, V Subbiah
No abstract text is available yet for this article.
January 31, 2019: Annals of Oncology: Official Journal of the European Society for Medical Oncology
journal
journal
30452
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"